4 results match your criteria: "University of Sciences Techniques and Technologies of Bamako - USTTB[Affiliation]"
eNeurologicalSci
June 2017
Department of Neurology, Gabriel Touré Teaching Hospital, PO Box: 267, Bamako, Mali.
Migraine is a debilitating but benign disease that can affect the quality of life of patients, disrupt the emotional relationships and impact on educational and vocational activities. The aim of our work was to study the epidemiology and impact of migraine in schools in the urban district of GAO in Mali. This is a cross-sectional study among students in the city of Gao.
View Article and Find Full Text PDFeNeurologicalSci
June 2016
Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, United States.
Introduction: Spinal muscular atrophy (SMA) and sporadic amyotrophic lateral sclerosis (SALS) are both motor neuron disorders. SMA results from the deletion of the survival motor neuron () 1 gene. High or low copy number and the absence of have been reported as risk factors for the development or severity of SALS.
View Article and Find Full Text PDFJ Intern Med
May 2014
Malaria Research and Training Center, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.
Malaria is a life-threatening disease caused by parasites of the Plasmodium genus. In many parts of the world, the parasites have developed resistance to a number of antimalarial agents. Key interventions to control malaria include prompt and effective treatment with artemisinin-based combination therapies, use of insecticidal nets by individuals at risk and active research into malaria vaccines.
View Article and Find Full Text PDFJ Antimicrob Chemother
December 2012
Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, SEREFO, FMPOS, University of Sciences Techniques and Technologies of Bamako - USTTB, BP: 1805, Bamako, Mali.
Objectives: We describe the outcomes of second-line drug resistance profiles and predict the efficacy of drugs for third-line therapy in patients monitored without the benefit of plasma HIV-1 RNA viral load (VL) or resistance testing.
Methods: We recruited 106 HIV-1-infected patients after second-line treatment failure in Mali. VL was determined by the Abbott RealTime system and the resistance by the ViroSeq HIV-1 genotyping system.